Sequence 18 from Patent US 20100279918

General Information


DRACP ID  DRACP01317

Peptide Name   Sequence 18 from Patent US 20100279918

Sequence  WEAKLAKALAKALAKHLAKALAKALKACEA

Sequence Length  30

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01317

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C144H248N40O35S

Absent amino acids  DFGIMNPQRSTVY

Common amino acids  A

Mass  364938

Pl  10.68

Basic residues  8

Acidic residues  2

Hydrophobic residues  19

Net charge  6

Boman Index  -228

Hydrophobicity  28.33

Aliphatic Index  118

Half Life 
  Mammalian: 1 hour
  Yeast: 2 min
  E.coli: 2 min

Extinction Coefficient cystines  5500

Absorbance 280nm  189.66

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2010/0279918 A1

Patent Title  Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.

Other Iinformation  Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status: Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;

Other Published ID  DE602007011901D1  EP1991586A1  EP1991586B1  WO2007108749A1  WO2007108749A8 




DRACP is developed by Dr.Zheng's team.